PMID- 33356703
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 62
IP  - 6
DP  - 2021 Jun
TI  - Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in 
      multiply relapsed (>/=2nd relapse) refractory myeloma: a multicenter real world UK 
      experience.
PG  - 1396-1404
LID - 10.1080/10428194.2020.1864355 [doi]
AB  - There are limited real world data on ixazomib, lenalidomide, and dexamethasone 
      (IRd) in multiply relapsed myeloma. We analyzed outcomes of 116 patients who 
      received IRd predominantly at second and subsequent relapse including those 
      refractory to proteasome inhibitors (PIs). With a median follow up 16.3 months, 
      the overall response rate was 66.9%; median progression-free survival (PFS) was 
      17.7 months with median overall survival (OS) not reached (NR). PFS and OS were 
      significantly shorter in advanced disease (PFS; 12.6 vs. 21.2 months (p = .01), 
      OS; 15.9 months vs. NR (p = .01) for ISS3 vs. ISS 1&2, respectively). PFS and OS 
      were significantly shorter in clinical high risk (CHR) compared to standard risk 
      (SR) patients (PFS; 9.3 months vs. NR (p = .001), OS; 11.5 months vs. NR 
      (p < .001), respectively). There was a trend toward shorter PFS in PI-refractory 
      patients 13.7 vs. 19.6 months for non-PI refractory (p = .2). The triplet 
      combination was generally well tolerated.
FAU - Maouche, Nadjoua
AU  - Maouche N
AD  - Department of Haematology, Oxford University Hospitals NHS Foundation Trust, 
      Oxford, UK.
FAU - Kishore, Bhuvan
AU  - Kishore B
AD  - Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, 
      Birmingham, UK.
FAU - Jenner, Matthew W
AU  - Jenner MW
AD  - Department of Haematology, University Hospital Southampton NHS Foundation Trust, 
      Southampton, UK.
FAU - Boyd, Kevin
AU  - Boyd K
AD  - Department of Haemato-Oncology, The Royal Marsden Hospital, Sutton, UK.
FAU - Bhatti, Zara
AU  - Bhatti Z
AD  - Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, 
      Birmingham, UK.
FAU - Bird, Sarah Anne
AU  - Bird SA
AD  - Department of Haemato-Oncology, The Royal Marsden Hospital, Sutton, UK.
FAU - Chander, Gurvin
AU  - Chander G
AD  - Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, 
      Birmingham, UK.
FAU - Robinson, Rebecca
AU  - Robinson R
AD  - Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, 
      Birmingham, UK.
FAU - Vallance, Grant D
AU  - Vallance GD
AD  - Department of Haematology, Oxford University Hospitals NHS Foundation Trust, 
      Oxford, UK.
FAU - Offer, Mark
AU  - Offer M
AD  - Department of Haematology, Frimley Health NHS Foundation Trust, Frimley, UK.
FAU - Kothari, Jaimal
AU  - Kothari J
AD  - Department of Haematology, Oxford University Hospitals NHS Foundation Trust, 
      Oxford, UK.
FAU - Peniket, Andy
AU  - Peniket A
AD  - Department of Haematology, Oxford University Hospitals NHS Foundation Trust, 
      Oxford, UK.
FAU - Aitchison, Robin
AU  - Aitchison R
AD  - Department of Haematology, Buckinghamshire Healthcare NHS Trust, Bucks, UK.
FAU - Dungarwalla, Moez
AU  - Dungarwalla M
AD  - Department of Haematology, Milton Keynes University Hospital NHS Foundation 
      Trust, Milton Keynes, UK.
FAU - Collings, Freya
AU  - Collings F
AD  - Department of Haematology, Great Western Hospitals NHS Foundation Trust, Swindon, 
      UK.
FAU - Bygrave, Ceri
AU  - Bygrave C
AD  - Department of Haematology, University Hospital of Wales, Cardiff, UK.
FAU - Ramasamy, Karthik
AU  - Ramasamy K
AD  - Department of Haematology, Oxford University Hospitals NHS Foundation Trust, 
      Oxford, UK.
LA  - eng
GR  - DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201225
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Boron Compounds)
RN  - 71050168A2 (ixazomib)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - F0P408N6V4 (Lenalidomide)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Boron Compounds
MH  - Dexamethasone/therapeutic use
MH  - Glycine/analogs & derivatives
MH  - Humans
MH  - Lenalidomide/therapeutic use
MH  - *Multiple Myeloma/drug therapy
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - United Kingdom
OTO - NOTNLM
OT  - Refractory
OT  - effectiveness
OT  - ixazomib
OT  - lenalidomide
OT  - real world
OT  - safety
EDAT- 2020/12/29 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/12/28 10:10
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/12/28 10:10 [entrez]
AID - 10.1080/10428194.2020.1864355 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2021 Jun;62(6):1396-1404. doi: 10.1080/10428194.2020.1864355. Epub 
      2020 Dec 25.